GlassScriptPhysician profile
Sydney Dunham Moore
NPI 1952993867
$8,811.14
in general payments reported to CMS, 2019-2025
25 companies · $2,162 in 2025
The $2,162 reported for 2025 was more than what 96% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,474 · 2022: $1,564 · 2023: $1,745 · 2024: $1,865 · 2025: $2,162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,243 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,440 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,242.83 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,440.00 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $6,091.83 | 2021-2025 | Interstim, Altaviva |
| Janssen Biotech, INC. | $374.21 | 2022-2024 | Erleada, Akeega |
| Teleflex LLC | $365.93 | 2021-2022 | |
| Dendreon Pharmaceuticals LLC | $295.89 | 2021-2025 | Provenge |
| Endo Pharmaceuticals INC. | $220.49 | 2021-2023 | Xiaflex, Aveed |
| Sumitomo Pharma America, INC. | $215.24 | 2023-2025 | Orgovyx, Gemtesa |
| Astrazeneca Pharmaceuticals LP | $143.87 | 2022-2025 | Lynparza |
| Myriad Genetic Laboratories, INC. | $139.94 | 2022 | |
| Coloplast Corp | $132.12 | 2024 | |
| Myovant Sciences INC. | $125.65 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $99.81 | 2021 | |
| Astellas Pharma US INC | $99.57 | 2021-2023 | Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $93.67 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $76.34 | 2022-2025 | Keytruda |
| Urovant Sciences INC | $66.01 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verity Pharmaceuticals INC. | $43.83 | 2025 | Tlando |
| Pfizer INC. | $34.19 | 2022 | |
| Caris Mpi, INC. | $33.52 | 2025 | Mi Cancer Seek |
| Antares Pharma, INC. | $29.99 | 2022 | |
| Ambu INC. | $28.94 | 2021 | |
| Abc Home Medical Supply, INC. | $24.31 | 2023 | |
| Endo USA, INC. | $23.03 | 2025 | Xiaflex |
| Halozyme INC | $18.84 | 2023 | |
| Progenics Pharmaceuticals, INC. | $17.31 | 2025 | |
| Urogen Pharma, INC. | $16.61 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sydney Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.